The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.a

Respiratory tract infection incl. pneumonia

A modest increase in risk has been found in some but not all studies. No opportunistic infection described yet (08/2015)

Publications

Khan N, Pernes T, Weiss A, Trivedi C, Patel M, Xie D, Yang YX

Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study.

Advances in therapy 2021 Apr 12;; — 2021 Apr 12

Bickston SJ, Behm BW, Tsoulis DJ, Cheng J, MacDonald JK, Khanna R, Feagan BG

Vedolizumab for induction and maintenance of remission in ulcerative colitis.

The Cochrane database of systematic reviews 2014 Aug 08;;CD007571 — 2014 Aug 08 — CD007571

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A,

Vedolizumab as induction and maintenance therapy for Crohn's disease.

The New England journal of medicine 2013 Aug 22;369;711-21 — 2013 Aug 22 — 711-21